A17

A17 is a bile acid analog with anti-non-alcoholic steatohepatitis (NASH) and anti-inflammatory activities. A17 reduces fatty acid (FA) uptake and promotes FA oxidation though inhibiting fatty acid translocase (Cd36) expression and activating AMPKα. A17 can be used for NASH research[1].

Product Specifications

CAS Number

[2568186-47-8]

UNSPSC

12352211

Target

AMPK

Type

Reference compound

Related Pathways

Epigenetics; PI3K/Akt/mTOR

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/a17.html

Purity

99.4

Solubility

10 mM in DMSO

Smiles

O=CO[C@@H]1[C@]2([H])[C@@](CC[C@]3([C@@]2([H])CC[C@]3([H])[C@H](C)CCC(N[C@H](CO)C(C)C)=O)C)([H])[C@@]4([C@](C[C@@H](CC4)OC=O)([H])C1)C

Molecular Formula

C31H51NO6

Molecular Weight

533.75

References & Citations

[1]Wang Y, et al. A novel bile acid analog, A17, ameliorated non-alcoholic steatohepatitis in high-fat diet-fed hamsters. Toxicol Appl Pharmacol. 2020 Oct 1;404:115169.